NASDAQ · FATE
Fate Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for FATE: Nov 12, 2026
Fate Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.27. The reported EPS for the same quarter last year was $-0.27.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.27 | $-0.26 | $-0.28 | 4 |
| Dec 2026 | $-0.30 | $-0.28 | $-0.34 | 4 |
| Mar 2027 | $-0.25 | $-0.23 | $-0.28 | 2 |
| Jun 2027 | $-0.26 | $-0.23 | $-0.29 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · Zacks- RTTNews · Oct 12, 8:26 AM EDTFate Therapeutics Taps Jamie Harrell To Guide Commercial Strategy For FT819 And FT839(RTTNews) – Fate Therapeutics, Inc. (FATE) announced the appointment of Jamie Harrell as Senior Vice President of Market Development and Commercial Operations, effective October 12, 2026. Harrell will lead the company's commercial strategy across its autoimmune disease and oncolo
- RTTNews · Sep 25, 8:07 AM EDTFate Therapeutics Receives $15M CIRM Grant To Advance FT819 In Lupus Nephritis(RTTNews) – Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company developing iPSC-derived cellular immunotherapies, announced that the California Institute for Regenerative Medicine (CIRM) awarded the company a $15.0 million CLIN2 grant to support the clinica
- RTTNews · Sep 16, 9:29 AM EDTFate Therapeutics To Present Off-The-Shelf CAR T Portfolio At ACR Convergence 2026(RTTNews) – Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company developing iPSC-derived cellular immunotherapies, announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at ACR Convergence 2026, scheduled
- The Motley Fool · Aug 31, 5:04 AM EDTJohnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.J&J's portfolio primarily includes small biotech and medtech companies.
- RTTNews · Aug 14, 11:27 AM EDTFate Therapeutics Advances FT819 Doses First Patient In Lupus Nephritis Trial(RTTNews) – Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies, announced the initiation of its Phase 2 RECLAIM-LN clinical trial evaluating FT819 in patients with refractory moderate-to-severe systemic Lup
- Zacks · Aug 13, 9:45 AM EDTFate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue EstimatesFate Therapeutics (FATE) delivered earnings and revenue surprises of +10.71% and +108.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 9:50 AM EDTMonte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue EstimatesMonte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -72.00% and -65.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 10, 3:12 AM EDTFate Gets FDA IND Clearance For FT839 To Initiate Phase 1/2 Trial In Autoimmune Diseases(RTTNews) – Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for FT839, an off-the-shelf CAR T-cell product candidate targeting CD19 and CD38.
- Zacks · May 13, 9:40 AM EDTFate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue EstimatesFate Therapeutics (FATE) delivered earnings and revenue surprises of +10.87% and -25.77%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 7:05 PM EDTCAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue EstimatesCAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 6, 10:00 AM EDTFoghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseFoghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · May 6, 9:30 AM EDTNovavax (NVAX) Reports Q1 Loss, Beats Revenue EstimatesNovavax (NVAX) delivered earnings and revenue surprises of +75.68% and +100.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Fate Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.